Adenosine Therapeutics gets cash for DES (drug-eluting stent) development
This article was originally published in Clinica
US pharmaceutical firm Adenosine Therapeutics has joined the growing number of manufacturers hoping to cash in on the lucrative drug-eluting stent (DES) sector for preventing restenosis - the re-clogging of arteries.
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.